Aprepitant placebo

DRUG3 trials

Sponsors

University of Pennsylvania, Merck Sharp & Dohme LLC

Conditions

HIV InfectionNauseaVomiting

Phase 1

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose

CompletedNCT01300988

University of PennsylvaniaHIV Infection

Start: 2010-12-31End: 2013-08-31Updated: 2016-06-03

Phase 4

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

CompletedNCT01636947

Merck Sharp & Dohme LLCNausea, Vomiting

Start: 2012-12-12End: 2014-08-04Updated: 2018-09-25

Unknown Phase

Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients

CompletedNCT00956215

University of PennsylvaniaNausea, Vomiting

Start: 2010-05-31End: 2012-01-31Updated: 2012-02-16

Related Papers

Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.

2016-11-0811 citations

A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.

2011-09-0821 citations